Senexin A is a natural product and the earliest CDK8 inhibitor, which not only inhibits p21-stimulated transcription in vitro and in vivo but also suppresses the production of cytokines from damaged cells and the paracrine activity that damages both tumor and normal cells during chemotherapy. The gene discussed is CDK8; the disease is neoplasm.